Publications

Hall K, Lazaryan A, Der Laan MV, Lee CJ, Logan AC, Gruber S, Kabadi S, Khan I, Nicholls C, Rota LM, Nikai E, Ponomareva E, Koumas A, Waller EK. Efficacy and Safety of Belumosudil as Compared with Best Available Therapy for the Treatment of cGVHD in the US. Blood advances. 2025. PMID: 40875591

O'Connor TE, Lin C, Roloff GW, Zhang A, Miller K, Aldoss I, Kopmar NE, Dekker SE, Gupta VK, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Sutherland K, Dykes KC, Ahmed M, Chen E, Zambrano H, Bradshaw D, Mercadal S, Schwartz M, Tracy S, Connor MP, Kubiak M, Mukherjee A, Majhail N, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy P, Blunk B, Logan AC, Ladha A, Advani AS, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, O'Dwyer KM, Hill LC, Sasine J, Oliai C, Solh MM, Lee CJ, Kota VK, Koura D, Kumaran MV, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Bishop MR, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly LS, Tsai SB, Dholaria B. The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Bone marrow transplantation. 2025. PMID: 40849364

Nira Krasnow, Michelle Jayaraj, Mia Salans, Kelsey Kuwahara, Maggie Zhou, Samantha Fisch, Lauren Boreta, Steve Braunstein, Ramin Morshed, Harish Vasudevan, Jo Chien, Melanie Majure, Hope Rugo, Michelle Melisko, Laura Huppert. TRLS-13 CLINICAL CHARACTERISTICS AND OVERALL SURVIVAL OF PATIENTS WITH METASTATIC BREAST CANCER AND BRAIN METASTASES: A SINGLE CENTER RETROSPECTIVE COHORT STUDY. Neuro-oncology advances. 2025. PMID:

Brooks TR, Zabor EC, Bedelu Y, Yang X, Karimi YH, Nedved AN, Wang Y, Dave NK, Landsburg DJ, Baron K, Hu B, Trotier D, Pophali PA, Miller J, Grover NS, Reinert C, Major A, Schwarz T, Patel K, Salafian K, Ayers EC, Sundaram S, Brody JD, McKenna M, Tiger YKR, Sears-Smith M, Ghosh N, Peterson C, Khan C, Bliven SP, Narkhede M, Gibson A, Kline J, Munoz J, Garza Morales R, Ho C, Smith SD, Niu A, Hernandez-Ilizaliturri FJ, Chinyengetere F, Dave SS, Abdel-Razeq N, Alhaj Moustafa M, Caimi P, Hill BT. Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab. Blood. 2025. PMID: 40663785

Wong MK, Milhem MM, Sacco JJ, Michels J, In GK, Couselo EM, Schadendorf D, Beasley GM, Niu J, Chmielowski B, Wise-Draper TM, Bowles TL, Tsai KK, Lebbé C, Gaudy-Marqueste C, Middleton MR, Skolariki A, Samson A, Chesney JA, VanderWalde AM, Zakharia Y, Harrington KJ, Appleton E, Bommareddy PK, Zhu J, Viana M, Hou JW, Coffin RS, Robert C. RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40627813

Kwarteng LA, Lee AY, Sakafu L, Mango VL, Fundikira LS, Lyimo F, Kwikima U, Mushi BP, Van Loon K, Minja FJ. Global radiology: Building equitable and effective partnerships with low and middle-income countries. Clinical imaging. 2025. PMID: 40633489

Miller CR, Huang Y, Allan JN, Bhat SA, Bond D, Brander D, Byrd JC, Chavez J, Chong E, Danilov A, Dowling MR, Dvorak-Kornaus K, Hampel PJ, Ho C, Islam P, Malakhov N, Matasar M, Miller S, Parikh SA, Rabe KG, Rhodes JM, Roeker LE, Rogers KA, Saha A, Skarbnik A, Scott H, Schade J, Shadman M, Shouse G, Stephens DM, Thompson MC, Thompson PA, Wang Y, Woyach JA, Yano M, Omer Z, Kittai AS. Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era. American journal of hematology. 2025. PMID: 40600589

Yang H, Song H, Yip E, Gilpatrick T, Chang K, Allegakoen P, Lu KL, Hui K, Pham JH, Kasap C, Kumar V, Gayle J, Stohr BA, Cornelia Ding CK, Wiita AP, Meng MV, Chou J, Porten SP, Huang FW. Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression. Nature communications. 2025. PMID: 40527915

H. Geng, M. Randall, A. Ballapuram, L. Chen, C. Yung, M. Lu, C. Lowell, J. L. Rubenstein. THE TOLL-LIKE RECEPTOR 7/8 PATHWAY HAS PROGNOSTIC SIGNIFICANCE AND IS A THERAPEUTIC TARGET IN CNS LYMPHOMAS. Hematological Oncology. 2025. PMID:

D. A. Solomon, H. Geng, M. Randall, R. Sobel, J. Cleveland, A. Ballapuram, L. Chen, M. Lu, S. Cha, C. Lowell, W. P. Devine, J. L. Rubenstein. THERAPY-DRIVEN EVOLUTION AND INTRATUMORAL GENETIC HETEROGENEITY IN CNS LYMPHOMAS. Hematological Oncology. 2025. PMID:

Nikita Baclig, Andrew Soliman, Saya Jacob, Alexis LeVee, Samantha Fisch, Carolyn Face, Madhuri Chengappa, Saliha Chaudhry, Dame Idossa, Laura Huppert, Laura Quintal, Michelle Melisko, Melanie Majure, Jo Chien, Joanne Mortimer, Anne Blaes, Hope S. Rugo, Melissa Lechner, Kelly E. McCann. Abstract P1-04-07: Incidence and Risk Factors of Immune-Related Adverse Events in Metastatic Breast Cancer Patients: Findings from a Multi-Institutional Study. Clinical Cancer Research. 2025. PMID:

Madhuri Chengappa, Thejaswi K Poonacha, Nikitha Vobugari, Go Nishikawa, Saya Jacob, Samantha Fisch, Carolyn Face, Alexis LeVee, Nikita V. Baclig, Andrew Soliman, Laura Huppert, Laura Quintal, Michelle Melisko, Melanie Majure, Jo Chien, Joanne Mortimer, Kelly McCann, Hope S. Rugo, Dame Idossa, Anne Blaes. Abstract P1-12-04: Correlation between Immune-Related Adverse Events (irAE) and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Immune Checkpoint Inhibitors (ICI): a multi-institutional study. Clinical Cancer Research. 2025. PMID:

Laura A. Huppert, Kelsey Kuwahara, Maggie Zhou, Mia Salans, Samantha Fisch, Jo Chien, Melanie Majure, Hope Rugo, Lauren Boreta, Steve E. Braunstein, Ramin A. Morshed, Harish N. Vasudevan, Michelle E. Melisko. Abstract P5-10-01: Demographic, Clinical Characteristics, and Overall Survival of Patients with Metastatic Breast Cancer and Brain Metastases: A Single Center Retrospective Cohort Study. Clinical Cancer Research. 2025. PMID:

Samantha Fisch, Joshua Chin, Laura Quintal, Melanie Majure, Michelle Melisko, Jo Chien, Hope S. Rugo, Laura A. Huppert. Abstract P5-12-25: Single-center retrospective cohort study evaluating neutropenia and growth factor use with sacituzumab govitecan in patients with HR+/HER2- and triple negative metastatic breast cancer. Clinical Cancer Research. 2025. PMID:

Alexis LeVee, Saya Jacob, Samantha Fisch, Carolyne Face, Madhuri Chengappa, Saliha Chaudhry, Nikita Baclig, Andrew Soliman, Nora Ruel, Megan Wong, Karen Tsai, Irene Kang, Laura Huppert, Laura Quintal, Michelle Melisko, Melanie Majure, Jo Chien, Melissa Lechner, Dame Idossa, Anne Blaes, Kelly McCann, Hope S. Rugo, Joanne Mortimer. Abstract PS5-03: Incidence and Risk Factors of Immune-Related Adverse Events in Early-Stage Breast Cancer Patients: Findings from a Multi-Institutional Study. Clinical Cancer Research. 2025. PMID:

Tien JC, Zhai Y, Wu R, Zhang Y, Chang Y, Cheng Y, Todd AJ, Wheeler CE, Li S, Mannan R, Cheng C, Magnuson B, Cruz G, Cao Y, Mahapatra S, Stolfi C, Cao X, Su F, Wang R, Yang J, Zhou L, Qiao Y, Xiao L, Cieslik M, Wang X, Wang Z, Chou J, Fearon ER, Ding K, Cho KR, Chinnaiyan AM. Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 2025. PMID: 40504161

Liao N, Li C, Gradishar WJ, Klimberg VS, Roshal JA, Yuan T, Agarwala SS, Valero VK, Swain SM, Margenthaler JA, Rubio IT, Hurvitz SA, Geyer CE, Lin NU, Rugo HS, Zhang G, Liu N, Balch CM. Accuracy and Reproducibility of ChatGPT Responses to Breast Cancer Tumor Board Patients. JCO clinical cancer informatics. 2025. PMID: 40466030

Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, Deol A, Agha M, Berdeja JG, Lesokhin AM, Liegel JJ, Rossi A, Lieberman-Cribbin A, Usmani SZ, Dhakal B, Parekh S, Li H, Wang F, Montes de Oca R, Plaks V, Sun H, Banerjee A, Schecter JM, Lendvai N, Madduri D, Lengil T, Zhu J, Koneru M, Akram M, Patel N, Costa Filho O, Jakubowiak AJ, Voorhees PM. Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40459151

Soragni A, Knudsen ES, O'Connor TN, Tognon CE, Tyner JW, Gini B, Kim D, Bivona TG, Zang X, Witkiewicz AK, Goodrich DW, Jiang D, Gammon ST, Willey CD, Boutros PC, Sandulache VC, Osman AA, Myers JN, Mehla K, Singh PK, Chan KS, Gao H, Marathe H, National Cancer Institute (NCI) Acquired Resistance to Therapy Network (ARTNet). Acquired resistance in cancer: towards targeted therapeutic strategies. Nature reviews. Cancer. 2025. PMID: 40461793

He J, Tsuboi M, Weder W, Chen KN, Hochmair MJ, Shih JY, Lee SY, Lee KY, Nhung NV, Saeteng S, Liu L, Xing L, Gia NH, Murakami S, Han Y, Saavedra MP, Yoon SH, Teixeira CHA, Escriu C, Martinez-Marti A, Blakely CM, Yatabe Y, Dacic S, Rukazenkov Y, Huang X, Dayal A, Chaft JE, NeoADAURA Investigators. Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40454705